Diego Bulcão Visco
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Diego Bulcão Visco has a total of 61 co-authors. Here are the top co-authors by number of shared publications:
- Ana Elisa Toscano
Federal University of Pernambuco
11 shared publications - Omar Guzman-Quevedo
Instituto Tecnológico Superior de Tacámbaro, Tacámbaro, México
5 shared publications Raul Manhães-De-Castro
Graduate Program in Nutrition (Posnutri), Health Sciences Center, Federal University of Pernambuco, Recife, Brazil
5 shared publications- Raul Manhães-De-Castro
Studies in Nutrition and Phenotypic Plasticity Unit, Center for Health Sciences, Federal University of Pernambuco, Recife-Pernambuco 50670-420, Brazil
4 shared publications Diego Cabral Lacerda
Studies in Nutrition and Phenotypic Plasticity Unit, Department of Nutrition Federal University of Pernambuco Recife Brazil
3 shared publications- Bárbara Juacy Rodrigues Costa de Santana
Studies in Nutrition and Phenotypic Plasticity Unit, Department of Nutrition Federal University of Pernambuco Recife Brazil
2 shared publications
Latest Publications
- 15 August 2025
- Published by Elsevier in Neuroscience
- Vol. 584, 113-126
The impact of social isolation due to the COVID-19 pandemic on functional performance, fall risk, and gait in individuals with Parkinson’s Disease: a systematic review
- 15 August 2025
- Published by Elsevier in Neuroscience
- Vol. 584, 113-126
The impact of social isolation due to the COVID-19 pandemic on functional performance, fall risk, and gait in individuals with Parkinson’s Disease: a systematic review
- 16 June 2023
- Published by Elsevier
- p. 873-889
Tryptophan as a supplement in cerebral palsy
- 28 December 2022
- Published by Taylor & Francis in Nutritional Neuroscience
- Vol. 27 (1) , 20-41
Neonatal kaempferol exposure attenuates impact of cerebral palsy model on neuromotor development, cell proliferation, microglia activation, and antioxidant enzyme expression in the hippocampus of rats
This study aims to assess the effect of neonatal treatment with kaempferol on neuromotor development, proliferation of neural precursor cells, the microglia profile, and antioxidant enzyme gene exp...
- 28 December 2022
- Published by Taylor & Francis in Nutritional Neuroscience
- Vol. 27 (1) , 20-41
Neonatal kaempferol exposure attenuates impact of cerebral palsy model on neuromotor development, cell proliferation, microglia activation, and antioxidant enzyme expression in the hippocampus of rats
This study aims to assess the effect of neonatal treatment with kaempferol on neuromotor development, proliferation of neural precursor cells, the microglia profile, and antioxidant enzyme gene exp...
- 20 November 2022
- Published by Wiley in International Journal of Developmental Neuroscience
- Vol. 83 (1) , 80-97
Neonatal kaempferol exposure attenuates gait and strength deficits and prevents altered muscle phenotype in a rat model of cerebral palsy
Cerebral palsy (CP) is characterized by brain damage at a critical period of development of the central nervous system, and, as a result, motor, behavioural and learning deficits are observed in those affected. Flavonoids such as kaempferol have demonstrated potential anti‐inflammatory and neuroprotective properties for neurological disorders. This study aimed to assess the effects of neonatal treatment with kaempferol on the body development, grip strength, gait performance and morphological and biochemical phenotype of skeletal muscle in rats subjected to a model of CP. The groups were formed by randomly allocating male Wistar rats after birth to four groups as follows: C = control treated with vehicle, K = control treated with kaempferol, CP = CP treated with vehicle and CPK = CP treated with kaempferol. The model of CP involved perinatal anoxia and sensorimotor restriction of the hind paws during infancy, from the second to the 28th day of postnatal life. Treatment with kaempferol (1 mg/kg) was performed intraperitoneally during the neonatal period. Body weight and length, muscle strength, gait kinetics and temporal and spatial parameters were evaluated in the offspring. On the 36th day of postnatal life, the animals were euthanized for soleus muscle dissection. The muscle fibre phenotype was assessed using the myofibrillar ATPase technique, and the muscle protein expression was measured using the Western blot technique. A reduction in the impact of CP on body phenotype was observed, and this also attenuated deficits in muscle strength and gait. Treatment also mitigated the impact on muscle phenotype by preventing a reduction in the proportion of oxidative fibres and in the histomorphometric parameters in the soleus muscle of rats in the CP group. The results demonstrate that neonatal treatment with kaempferol attenuated gait deficits and impaired muscle strength and muscle maturation in rats subjected to a model of CP.
- 20 November 2022
- Published by Wiley in International Journal of Developmental Neuroscience
- Vol. 83 (1) , 80-97
Neonatal kaempferol exposure attenuates gait and strength deficits and prevents altered muscle phenotype in a rat model of cerebral palsy
Cerebral palsy (CP) is characterized by brain damage at a critical period of development of the central nervous system, and, as a result, motor, behavioural and learning deficits are observed in those affected. Flavonoids such as kaempferol have demonstrated potential anti‐inflammatory and neuroprotective properties for neurological disorders. This study aimed to assess the effects of neonatal treatment with kaempferol on the body development, grip strength, gait performance and morphological and biochemical phenotype of skeletal muscle in rats subjected to a model of CP. The groups were formed by randomly allocating male Wistar rats after birth to four groups as follows: C = control treated with vehicle, K = control treated with kaempferol, CP = CP treated with vehicle and CPK = CP treated with kaempferol. The model of CP involved perinatal anoxia and sensorimotor restriction of the hind paws during infancy, from the second to the 28th day of postnatal life. Treatment with kaempferol (1 mg/kg) was performed intraperitoneally during the neonatal period. Body weight and length, muscle strength, gait kinetics and temporal and spatial parameters were evaluated in the offspring. On the 36th day of postnatal life, the animals were euthanized for soleus muscle dissection. The muscle fibre phenotype was assessed using the myofibrillar ATPase technique, and the muscle protein expression was measured using the Western blot technique. A reduction in the impact of CP on body phenotype was observed, and this also attenuated deficits in muscle strength and gait. Treatment also mitigated the impact on muscle phenotype by preventing a reduction in the proportion of oxidative fibres and in the histomorphometric parameters in the soleus muscle of rats in the CP group. The results demonstrate that neonatal treatment with kaempferol attenuated gait deficits and impaired muscle strength and muscle maturation in rats subjected to a model of CP.
- 14 December 2021
- Published by Taylor & Francis in Nutritional Neuroscience
- Vol. 26 (1) , 25-39
Dietary flavonoid kaempferol reduces obesity-associated hypothalamic microglia activation and promotes body weight loss in mice with obesity
Background: Obesity results from an unbalance in the ingested and burned calories. Energy balance (EB) is critically regulated by the hypothalamic arcuate nucleus (ARC) by promoting appetite or anorectic actions. Hypothalamic inflammation, driven by high activation of the microglia, has been reported as a key mechanism involved in the development of diet-induced obesity. Kaempferol (KF), a flavonoid-type polyphenol present in a large number of fruits and vegetables, was shown to regulate both energy metabolism and inflammation. Objectives: In this work, we studied the effects of both the central and peripheral treatment with KF on hypothalamic inflammation and EB regulation in mice with obesity. Methods: Obese adult mice were chronically (40 days) treated with KF (0.5 mg/kg/day, intraperitoneally). During the treatment, body weight, food intake (FI), feed efficiency (FE), glucose tolerance, and insulin sensitivity were determined. Analysis of microglia activation in the ARC of the hypothalamus at the end of the treatment was also performed. Body weight, FI, and FE changes were also evaluated in response to 5µg KF, centrally administrated. Results: Chronic administration of KF decreased ∼43% of the density, and ∼30% of the ratio, of activated microglia in the arcuate nucleus. These changes were accompanied by body weight loss, decreased FE, reduced fasting blood glucose, and a tendency to improve insulin sensitivity. Finally, acute central administration of KF reproduced the effects on EB triggered by peripheral administration. Conclusion: These findings suggest that KF might fight obesity by regulating central processes related to EB regulation and hypothalamic inflammation. GRAPHICAL ABSTRACT
- 14 December 2021
- Published by Taylor & Francis in Nutritional Neuroscience
- Vol. 26 (1) , 25-39
Dietary flavonoid kaempferol reduces obesity-associated hypothalamic microglia activation and promotes body weight loss in mice with obesity
Background: Obesity results from an unbalance in the ingested and burned calories. Energy balance (EB) is critically regulated by the hypothalamic arcuate nucleus (ARC) by promoting appetite or anorectic actions. Hypothalamic inflammation, driven by high activation of the microglia, has been reported as a key mechanism involved in the development of diet-induced obesity. Kaempferol (KF), a flavonoid-type polyphenol present in a large number of fruits and vegetables, was shown to regulate both energy metabolism and inflammation. Objectives: In this work, we studied the effects of both the central and peripheral treatment with KF on hypothalamic inflammation and EB regulation in mice with obesity. Methods: Obese adult mice were chronically (40 days) treated with KF (0.5 mg/kg/day, intraperitoneally). During the treatment, body weight, food intake (FI), feed efficiency (FE), glucose tolerance, and insulin sensitivity were determined. Analysis of microglia activation in the ARC of the hypothalamus at the end of the treatment was also performed. Body weight, FI, and FE changes were also evaluated in response to 5µg KF, centrally administrated. Results: Chronic administration of KF decreased ∼43% of the density, and ∼30% of the ratio, of activated microglia in the arcuate nucleus. These changes were accompanied by body weight loss, decreased FE, reduced fasting blood glucose, and a tendency to improve insulin sensitivity. Finally, acute central administration of KF reproduced the effects on EB triggered by peripheral administration. Conclusion: These findings suggest that KF might fight obesity by regulating central processes related to EB regulation and hypothalamic inflammation. GRAPHICAL ABSTRACT
- 18 August 2021
- Published by Taylor & Francis in Nutritional Neuroscience
- Vol. 25 (11) , 2458-2460
Could polyphenols be used as a neuroprotector therapeutic agent in perinatal brain disorders?
Polyphenols are a group of bioactive compounds, essential for a variety of functions in plants. These natural compounds are commonly found in the human diet mainly in fruits, vegetables, cereals, c...
- 18 August 2021
- Published by Taylor & Francis in Nutritional Neuroscience
- Vol. 25 (11) , 2458-2460
Could polyphenols be used as a neuroprotector therapeutic agent in perinatal brain disorders?
Polyphenols are a group of bioactive compounds, essential for a variety of functions in plants. These natural compounds are commonly found in the human diet mainly in fruits, vegetables, cereals, c...
- 2 March 2021
- Published by Taylor & Francis in Nutritional Neuroscience
- Vol. 25 (8) , 1680-1696
Metabolic and neurological consequences of the treatment with polyphenols: a systematic review in rodent models of noncommunicable diseases
Noncommunicable diseases (NCDs) lead to drastic metabolic alterations with associated energy balance and body weight changes, two related physiological processes regulated by the brain. Polyphenol-...
- 2 March 2021
- Published by Taylor & Francis in Nutritional Neuroscience
- Vol. 25 (8) , 1680-1696
Metabolic and neurological consequences of the treatment with polyphenols: a systematic review in rodent models of noncommunicable diseases
Noncommunicable diseases (NCDs) lead to drastic metabolic alterations with associated energy balance and body weight changes, two related physiological processes regulated by the brain. Polyphenol-...
- Open Access
- 1 November 2020
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 131, 110727
Early life fluoxetine treatment causes long-term lean phenotype in skeletal muscle of rats exposed to maternal lard-based high-fat diet
- 1 November 2020
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 131, 110727
Open AccessEarly life fluoxetine treatment causes long-term lean phenotype in skeletal muscle of rats exposed to maternal lard-based high-fat diet
- Open Access
- 31 October 2020
- Published by Research, Society and Development in Research, Society and Development
- Vol. 9 (11)
Perfil lipídico em crianças com sobrepeso e obesidade: uma revisão integrativa
Introdução: A obesidade infanto-juvenil cresce de forma relevante no mundo nas últimas décadas e está fortemente associada a várias anormalidades metabólicas, como: intolerância à glicose, hipertensão arterial e dislipidemia, sendo também fatores preponderantes para o desenvolvimento de doenças cardiovasculares e diabetes do tipo II. Objetivo: Identificar o perfil lipídico de crianças e adolescentes com sobrepeso e obesidade e verificar associação com doenças cardiometabólicas. Metodologia: Trata-se de revisão integrativa da literatura, onde foi realizada por meio de busca eletrônica nas bases de dados PubMed, BIREME e SciELO, de setembro a outubro de 2019. Identificou-se 255 artigos e por meio de critérios de elegibilidade, selecionou-se, no final, um total de 18. Resultados: Os resultados das análises bioquímicas dos artigos estudados confirmam a hipótese de que as alterações metabólicas já estão presentes na infância e adolescência. Conclusão: A literatura científica apresenta diversos trabalhos nos quais crianças e adolescentes com sobrepeso e obesidade apresentam concentrações aumentadas de lipídios circulantes, e afirmam maior prevalência de dislipidemia, quando comparados a eutróficos.
- 31 October 2020
- Published by Research, Society and Development in Research, Society and Development
- Vol. 9 (11)
Open AccessPerfil lipídico em crianças com sobrepeso e obesidade: uma revisão integrativa
Introdução: A obesidade infanto-juvenil cresce de forma relevante no mundo nas últimas décadas e está fortemente associada a várias anormalidades metabólicas, como: intolerância à glicose, hipertensão arterial e dislipidemia, sendo também fatores preponderantes para o desenvolvimento de doenças cardiovasculares e diabetes do tipo II. Objetivo: Identificar o perfil lipídico de crianças e adolescentes com sobrepeso e obesidade e verificar associação com doenças cardiometabólicas. Metodologia: Trata-se de revisão integrativa da literatura, onde foi realizada por meio de busca eletrônica nas bases de dados PubMed, BIREME e SciELO, de setembro a outubro de 2019. Identificou-se 255 artigos e por meio de critérios de elegibilidade, selecionou-se, no final, um total de 18. Resultados: Os resultados das análises bioquímicas dos artigos estudados confirmam a hipótese de que as alterações metabólicas já estão presentes na infância e adolescência. Conclusão: A literatura científica apresenta diversos trabalhos nos quais crianças e adolescentes com sobrepeso e obesidade apresentam concentrações aumentadas de lipídios circulantes, e afirmam maior prevalência de dislipidemia, quando comparados a eutróficos.